Featured Research

from universities, journals, and other organizations

Use of stent with bioabsorbable polymer examined

Date:
September 21, 2010
Source:
Cardiovascular Research Foundation
Summary:
Three-year data demonstrated that satisfactory clinical and safety outcomes of sirolimus eluting stents with a biodegradable polymer were sustained in a real world setting.

Three-year data demonstrated that satisfactory clinical and safety outcomes of sirolimus eluting stents with a biodegradable polymer were sustained in a real world setting. The results were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

"The three-year data from the CREATE study is further evidence that biodegradable polymers represent the future of stent design," said Yaling Han, MD, the lead investigator and Director in the Department of Cardiology, Shenyang Northern Hospital (Shenyang, China.) "This study demonstrates sustained clinical safety and efficacy of biodegradable-polymer based sirolimus eluting stents when used with 6 months of dual antiplatelet therapy in a 'real-world' setting."

The CREATE study was a post-marketing surveillance multi-center registry that demonstrated satisfactory angiographic (at 9 months) and clinical (at 12 and 18 months) outcomes of biodegradable polymer-based sirolimus eluting stents for real world patients. The aim of the study was to evaluate the 3-year clinical safety and efficacy outcomes in patients enrolled in the CREATE trial.

A total of 2077 patients, exclusively treated with EXCEL stents at 59 centers from 4 countries, were enrolled in the CREATE study. The recommended antiplatelet regimen was clopidogrel and aspirin for 6 months followed by chronic aspirin therapy.

The cumulative rates of major adverse cardiac events (MACE) were 2.7% at 1 year and 4.5% at 3 years. The rate of stent thrombosis with Academic Research Consortium definitions was 0.83% at 1 year and 1.53% at 3 years. At 6 months to 3 years, prolonged clopidogrel therapy (> 6 months) was not beneficial in reducing cumulative hazards of MACE (5.2% vs. 4.6%, log rank p=0.629) or stent thrombosis (1.5% vs. 0.6%, log rank p=0.052).

3-year outcome data will be presented during the Poster Abstracts Sessions at the Washington Convention Center.


Story Source:

The above story is based on materials provided by Cardiovascular Research Foundation. Note: Materials may be edited for content and length.


Cite This Page:

Cardiovascular Research Foundation. "Use of stent with bioabsorbable polymer examined." ScienceDaily. ScienceDaily, 21 September 2010. <www.sciencedaily.com/releases/2010/09/100921084547.htm>.
Cardiovascular Research Foundation. (2010, September 21). Use of stent with bioabsorbable polymer examined. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2010/09/100921084547.htm
Cardiovascular Research Foundation. "Use of stent with bioabsorbable polymer examined." ScienceDaily. www.sciencedaily.com/releases/2010/09/100921084547.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins